Gilead Sciences
Gilead Sciences and Kite Pharma Announce Layoffs, Closure of Seattle and Philadelphia Offices
Gilead Sciences, Kite Pharma, layoffs, office closures, Seattle, Philadelphia, biotech industry, restructuring
Gilead Sciences Surpasses Q3 Earnings and Sales Forecasts, Boosts Annual Outlook
Gilead Sciences, Q3 earnings, HIV drug sales, annual guidance, Biktarvy, Veklury, lenacapavir, HIV prevention
Gilead Withdraws Trodelvy for Bladder Cancer in US After Confirmatory Trial Failure
Gilead Sciences, Trodelvy, bladder cancer, urothelial carcinoma, FDA, accelerated approval, drug withdrawal
Gilead Expands HIV Drug Access, Yet Faces Criticism Over Exclusion of Middle-Income Countries
Gilead Sciences, HIV drug access, Lenacapavir, Generic licensing agreements, Middle-income countries exclusion, HIV prevention, Pre-exposure prophylaxis (PrEP)
Gilead Expands Access to Long-Acting HIV PrEP with Licensing Deals for Generic Lenacapavir
Gilead Sciences, lenacapavir, HIV PrEP, generic licensing, long-acting HIV prevention, global health access
Gilead’s Kite Unit Exits China CAR-T Joint Venture with Fosun
Gilead Sciences, Kite Pharma, Fosun Pharma, CAR-T cell therapy, joint venture, China, Yescarta
Gilead’s Kite Terminates China Cell Therapy Joint Venture with Fosun Pharma
Gilead Sciences, Kite Pharma, Fosun Pharma, cell therapy, joint venture, China, CAR-T therapy, Yescarta
Gilead Partners with Yuhan for $81M HIV Drug Ingredient Supply Deal
Gilead Sciences, Yuhan, HIV drug ingredients, $81M deal, pharmaceutical partnership
Gilead’s Twice-Yearly Lenacapavir Shows 96% HIV Risk Reduction, Paving Way for Regulatory Filings
Gilead Sciences, Lenacapavir, HIV Prevention, Twice-Yearly PrEP, Regulatory Filings, PURPOSE 2 Trial
Gilead Sciences and Genesis Therapeutics Collaborate on AI-Driven Small Molecule Drug Discovery
Gilead Sciences, Genesis Therapeutics, AI-driven drug discovery, small molecule therapies, strategic partnership, generative AI, drug development